Coriell Life Sciences

Genetic Analysis

Coriell Life Sciences is using pharmacogenomics to deliver precision medicine. Currently, the safety and efficacy of more than 200 prescription medications are known to be impacted by a patient’s genetics. Pharmacogenomics involves understanding how genes can influence a response to a drug. With people aged 65-69 taking on average 14 prescriptions, Coriell is striving to improve medication efficacy through DNA testing and reduce overall healthcare costs. To attain this, Coriell is using their population-scale Medication Safety Program, Corigen®, which provides actionable solutions informed by genetic knowledge. Coriell works with large employers, health plans, academic institutions and public organizations to develop and improve their precision medicine strategies.